Sign In
Buy MYO
$1.10
+0.0400 (+3.77%)
At Close: Jun 03, 2026
Myomo, Inc.: In Motion To Accelerating Revenue Growth
03:00am, Sunday, 10'th Mar 2024
Medicare decision created a multi-decade revenue growth opportunity. Soft Q1 guidance due to non-recurring timing issues. 2024 guidance gives only partial-year credit to reimbursement change.
Myomo, Inc. (MYO) Q4 2023 Earnings Call Transcript
08:10pm, Thursday, 07'th Mar 2024
Myomo, Inc. (NYSE:MYO) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
07:01pm, Thursday, 07'th Mar 2024
Myomo, Inc. (MYO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.29 per share a year ago.
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Thursday, 07'th Mar 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi
CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®
08:00am, Friday, 01'st Mar 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi
Myomo to Report Fourth Quarter Financial Results on March 7, 2024
04:05pm, Thursday, 29'th Feb 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi
Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
04:05pm, Friday, 19'th Jan 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi
Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
08:05am, Wednesday, 17'th Jan 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog
08:00am, Wednesday, 17'th Jan 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi
What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'
10:31am, Wednesday, 20'th Dec 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Myomo, Inc. (MYO) could be a great choice. It is one of the several stocks that passed through our "Recent Pric
7 Stock Winners That Are Up 1,000% or More in 2023
07:00am, Tuesday, 12'th Dec 2023
As you may already suspect, there are not a lot of stocks up 1000% year-to-date, but several stocks trading on major exchanges are up 1000% from their lows set earlier in the calendar year. There are
Myomo: Market Severely Undervaluing Opportunity
01:32pm, Friday, 01'st Dec 2023
Market undervalues MYO stock due to poor understanding of CMS process. MYO is able to generate revenues in excess of $100mm/yr. MYO valuation gap will close before February 2024, when the final CMS pr
3 Hot Penny Stocks to Buy in Q4 for Promising Potential
04:16pm, Monday, 20'th Nov 2023
Penny stocks are typically companies that are trading below $5 per share. These companies are ones that can be risky to invest in.
Myomo, Inc. (MYO) Q3 2023 Earnings Call Transcript
06:28pm, Tuesday, 07'th Nov 2023
Myomo, Inc. (MYO) Q3 2023 Earnings Call Transcript
Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations
04:05pm, Tuesday, 07'th Nov 2023
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi
